MedTrace Logo

Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

NCT04072302 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2019-08-28

No results posted yet for this study

Summary

This study is designed to investigate the safety and causal prophylactic efficacy of KAF156 in healthy subjects using a controlled human malaria infection model.

Conditions

Interventions

DRUG

KAF156

100 mg tablet, 20 mg tablet, 50 mg tablet

DRUG

Placebo

100 mg tablet, 20 mg tablet, 50 mg tablet

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-15
Primary Completion
2017-11-29
Completion
2017-11-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04072302 on ClinicalTrials.gov